Genetics of suicide

被引:232
作者
Bondy, B
Buettner, A
Zill, P
机构
[1] Univ Munich, Sect Psychiat Genet & Neurochem, Psychiat Clin, D-80336 Munich, Germany
[2] Univ Munich, Inst Legal Med, D-80336 Munich, Germany
关键词
suicide; serotonin; genetics; polymorphism; association studies;
D O I
10.1038/sj.mp.4001803
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The concept that genetic factors contribute to the complex trait of suicidal behaviour has stimulated much work aimed at identifying susceptibility genes. So far molecular genetic studies focused on the serotonergic pathway as the intent to die and the lethality of suicide acts were related to the serotonergic system. Two genes have so far emerged as being involved in the vulnerability for suicidality: first, the intronic polymorphisms (A218C or A779C) of the tryptophan hydroxylase 1 (TPH1) gene, which was suggested as a quantitative risk factor for suicidal behaviour; second, the insertion/deletion polymorphism of the serotonin transporter gene (5-HTTLPR), which does not seem to be involved in general suicidal behaviour, but in violent and repeated suicide attempts. The data have further shown that the MAOA gene, which is consistently associated with impulsive-aggressive personality traits, is not related to suicide but might induce violent methods in subjects with other suicide risk factors. Predominantly negative were the findings with any type of the serotonin receptors and inconsistent with catecholamine-synthesizing and -metabolizing enzymes or with the dopaminergic receptors. This paper reviews the status of current knowledge in this area, points to the weakness of the investigations and presents new approaches beyond the serotonergic system.
引用
收藏
页码:336 / 351
页数:16
相关论文
共 208 条
  • [1] Suicide attempts and the tryptophan hydroxylase gene
    Abbar, M
    Courtet, P
    Bellivier, F
    Leboyer, H
    Boulenger, JP
    Castelhau, D
    Ferreira, M
    Lambercy, C
    Mouthon, D
    Paoloni-Giacobino, A
    Vessaz, M
    Malafosse, A
    Buresi, C
    [J]. MOLECULAR PSYCHIATRY, 2001, 6 (03) : 268 - 273
  • [2] The 5HT1A receptor: Signaling, desensitization, and gene transcription
    Albert, PR
    Lembo, P
    Storring, JM
    Charest, A
    Saucier, C
    [J]. NEUROPSYCHOPHARMACOLOGY, 1996, 14 (01) : 19 - 25
  • [3] 5-HT1A receptors, gene repression, and depression: Guilt by association
    Albert, PR
    Lemonde, S
    [J]. NEUROSCIENTIST, 2004, 10 (06) : 575 - 593
  • [4] Distribution of platelet 5-HT2A receptor densities in suicidal and non-suicidal depressives and control subjects
    Alda, M
    Hrdina, PD
    [J]. PSYCHIATRY RESEARCH, 2000, 94 (03) : 273 - 277
  • [5] A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders
    Anguelova, M
    Benkelfat, C
    Turecki, G
    [J]. MOLECULAR PSYCHIATRY, 2003, 8 (06) : 574 - 591
  • [6] LOCALIZED ALTERATIONS IN PRESYNAPTIC AND POSTSYNAPTIC SEROTONIN BINDING-SITES IN THE VENTROLATERAL PREFRONTAL CORTEX OF SUICIDE VICTIMS
    ARANGO, V
    UNDERWOOD, MD
    GUBBI, AV
    MANN, JJ
    [J]. BRAIN RESEARCH, 1995, 688 (1-2) : 121 - 133
  • [7] The 5-HT2A receptor gene 102T/C polymorphism is associated with suicidal behavior in depressed patients
    Arias, B
    Gastó, C
    Catalán, R
    Gutiérrez, B
    Pintor, L
    Fañanás, L
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS, 2001, 105 (08): : 801 - 804
  • [8] A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia
    Arinami, T
    Gao, M
    Hamaguchi, H
    Toru, M
    [J]. HUMAN MOLECULAR GENETICS, 1997, 6 (04) : 577 - 582
  • [9] ASBERG M, 1976, ARCH GEN PSYCHIAT, V33, P1193
  • [10] A pilot genetic study of the continuum between compulsivity and impulsivity in females:: The serotonin transporter promoter polymorphism
    Baca-García, E
    Salgado, BR
    Segal, HD
    Lorenzo, CV
    Acosta, MN
    Romero, MA
    Hernández, MD
    Saiz-Ruiz, J
    Piqueras, JF
    de Leon, J
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2005, 29 (05) : 713 - 717